On Mar. 4, 2019, Vaccitech announced that it had been awarded a contract valued at $8.6 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services, for the advanced clinical development of its recombinant Modified Vaccinia Ankara (MVA) vaccine candidate for prevention of seasonal and pandemic influenza A.